通过修改醇的12侧链来显著切换蛋白质激酶C的激动剂/对抗剂活性
Reiko Wada1, Yutaka Suto, Motomu Kanai
1Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.
Journal of the American Chemical Society
|September 5, 2002
概括
修改醇的侧链极大地改变了蛋白激酶C (PKC) 的活性. 一个甘醇链产生了一个PKC抗剂,而一个醇链产生了一个强大的PKC抗剂,提供了新的抗癌治疗潜力.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白激酶C (PKC) 是细胞信号通路中的关键酶.
- 博 Ester 是已知的PKC激活剂,但它们的活性可以调节.
- 了解结构-活动关系是开发向治疗的关键.
研究的目的:
- 为了研究如何修改博的12侧链的水友性影响PKC激动剂和抗剂的活性.
- 探索这些修饰的醇作为抗癌剂的潜力.
主要方法:
- 合成具有不同12侧链 (例如,糖醇与醇) 的博 Ester.
- 检测PKC的对抗性和激动性活动.
- 使用Hela细胞/PBS缓冲系统进行分区测试以评估化合物行为.
主要成果:
- 博醇4,在12链上有一个甘醇,表现出强大的PKC抗活性.
- 博醇3,在12链上有一个醇,表现出强烈的PKC激活活性.
- 一个拟议的机制表明,醇-4作为PKC-醇复合物的转位毒素.
结论:
- 12侧链的水友性是醇活性 (激动剂与对抗剂) 的关键决定因素.
- 这种方法为开发选择性PKC抑制剂提供了一种战略.
- 修改后的博 Ester 作为抗癌疗法的药物化合物具有前途.
相关概念视频
Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Ligand Binding and Linkage
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...


